posted
NanoViricides, Inc. (Pink NNVC): Imagine having a nano-scale molecularly engineered "guided missile", about the size of a few billionth of a meter, that courses through the blood-stream, seeks its target e.g. a virus particle, attaches itself to the target, and then destroys the target completely. NanoViricides Website: http://www.nanoviricides.com/ NanoBio News: http://www.nanobiotechnews.com/ ...&... http://www.nanovip.com/directory/Detailed/1785.phpPosts: 1113 | Registered: Jun 2005
| IP: Logged |
posted
Vietnam Invites NanoViricides to Play Role in Battle against Bird Flu 8/22/2005 11:01:10 AM
NEW YORK, Aug 22, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC), announced today that the Government of Vietnam's National Institute of Hygiene and Epidemiology ("NIHE"), Vietnam's leading institute for the surveillance, control and prevention of infectious diseases, extended an invitation to the Company to help in the battle against bird flu.
The Company will meet with the key scientific persons in this governmental agency as part of the Country's effort to prepare adequately for potential outbreaks of this highly contagious and fatal disease. "NanoViricides has an approach that appears capable of making true viricides...you appear to have a unique technology...the potential for this approach is immense and important, as any outbreaks can be curtailed before they reach epidemic proportions," noted Dr. Nguyen Tran Hien, Director of NIHE. "We are interested in discussing further the potential of developing NanoViricides against the bird flu virus strains."
Dr. Anil Diwan, President of NanoViricides, added, "Our technology has elicited the notice of the senior science community in Vietnam, a country facing an uphill battle against this deadly epidemic. They are proactive in seeking out solutions, and have the support of the world to find ways to ensure that this does not become a pandemic issue. We are honored to join them in this fight."
"The Company is excited to field these commercial opportunities," noted Leo Ehrlich, CFO. "Joint venture work offers a potential for revenues and goal oriented research that advances the Company's core business and operational purpose against specific viral enemies. We will begin a relationship with Vietnam and the surrounding nations that will allow us to advance our technology and address specific issues facing the nations of the world."
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that it will license the products to major pharmaceutical companies.
SOURCE: NanoViricides, Inc. NanoViricides, Inc., New York Leo Ehrlich, 917-853-6440 leo@nanoviricides.com or Anil R. Diwan, Ph.D. adiwan@snet.net .
Posts: 1113 | Registered: Jun 2005
| IP: Logged |
NEW YORK, Sept. 20, 2005 (PRIMEZONE) -- NanoViricides, Inc. (Other OTC:NNVC.PK - News) announced today that the Company is actively developing its first NanoViricide(tm) drug, ``FluCide-I(tm).'' The Company expects to commence studies in external laboratories within a matter of weeks to verify the drug's effectiveness and basic safety profile against the influenza virus. Animal studies as well as cell culture studies will be initiated.
NanoViricides Presents at the Premiere Event of the Year for Connecticut's Technology Leaders Also, Pre-Clinical Studies to Begin on FluCide-I, Its Anti-Influenza Drug 9/28/2005 1:50:20 PM NEW YORK, Sept. 28, 2005, Sep 28, 2005 (PRIMEZONE via COMTEX) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced that its President, Dr. Anil Diwan, has been selected to present today to a group of select investors at the Connecticut Venture Group's Annual CVG Angel forum. Only thirty entrepreneurial businesses across all industries have been chosen by CVG this year.
The Connecticut Venture Group is sponsored by some of the leading organizations in the financial community such as Lehman Brothers, Pricewaterhouse and others. The goal of the group is to assist the development of high growth enterprises through the promotion of capital formation in Connecticut. Information on the group can be found at their website, www.cvg.org and www.ctinnovations.org
The company plans to begin pre-clinical studies on its first nanoviricide drug, FluCide-I, its anti-influenza drug, on October 11th. The animal trials will be supervised by Dr. Krishna Menon, Chief Regulatory Officer for the Company.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(tm) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. When a NanoViricide drug enters the patient's blood stream, each nanoscale micelle of the drug attacks and neutralizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus particle by the NanoViricide micelle, destroying it completely. The company plans to develop novel NanoViricide drugs first against HIV and Influenza, and anticipates that it will license the products to major pharmaceutical companies.
SOURCE: NanoViricides, Inc. NanoViricides, Inc., New York Leo Ehrlich 917-853-6440 leo*nanoviricides.com
posted
NanoViricides, Inc. to Tackle Asian Bird Flu 10/3/2005 1:19:01 PM WEST HAVEN, Conn., Oct 03, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced that it is moving rapidly forward with its strategy for combating Avian Flu. "If our FluCide-I influenza drug meets the initial expectations, we can modify it very quickly to develop a nanoviricide against the avian flu," explained Dr. Diwan, President, "We simply reset the nanoviricide's target to H5N1, the bird flu virus!" The Company has scheduled high-level meetings in December with Vietnam's senior government officials and scientists regarding avian flu. "This invitation by the Vietnamese government gives us an enormous advantage over most other companies, including large cap biotech firms," said the CEO, Eugene Seymour, MD, MPH. The Company anticipates having preclinical data available to share on its Flucide-I influenza (nanoviricide) drug and considers this a unique opportunity to access the wealth of information available in Vietnam on bird flu.</b>
Two days ago, the US Senate passed a $4 Billion bill to purchase TamiFlu(TM) (Roche) and also to pursue additional strategies for prevention as well as treatment. Tamiflu(TM) has limited effectiveness but remains the only means of treatment against avian flu at present. The Senate funding move came the same day the United Nations' new avian flu coordinator Dr. David Nabarro warned that a flu pandemic could kill millions of people worldwide.
"Developing targeted therapies for both usual Influenza and Avian Flu will enable the company to tap into the billions of dollars now available from both the Department of Defense and the Department of Homeland Security," Dr. Seymour continued, "We are now giving the highest priority to Influenza and Avian Flu."
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile.
SOURCE: NanoViricides, Inc. NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo*nanoviricides.com
posted
NanoViricides Featured in NanoBiotech News Special Report on Avian Flu "Just as penicillin brought on a major revolution in antibiotics, the first viricide will create a similar revolution" 10/12/2005 3:06:01 PM WEST HAVEN, Conn., Oct 12, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC), has announced that the Company was selected as the lead story in the October 12, 2005 edition of NanoBiotech News. The Company has secured rights for the electronic posting of the article which can be viewed free of charge, beginning tomorrow, by visiting http://www.nanoviricides.com
Excerpts from the article:
"We want to create the first viricide," ... "We believe we have it, but we won't be sure until we go through animal and human trials. Nevertheless, we are optimistic." Dr. Diwan notes that previous work in the lab has yielded "Certain kinds of proof of principal."
"Just as penicillin brought on a major revolution in antibiotics, the first viricide will create a similar revolution", Diwan predicts. "Just imagine; a viricide that attacks and destroys the virus particle itself."
"It is clear that if any one company were to develop a highly efficacious vaccine against avian flu, the financial rewards could be enormous."
Although the article mentions a four to six year regulatory timeline, the Company is hopeful that because FluCide-I targets a public health threat, it is possible it can receive special permission for humanitarian use in cooperation with the regulatory agencies.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile.
SOURCE: NanoViricides, Inc. NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo*nanoviricides.com
List of BIRD FLU hot stock !!! The stock will be very bullish in the next weeks and next months !!!!! NVAX NNVC.PK HEB QDEL (They make Bird Flu testing kit)
posted
News: NanoViricides Has Begun Preclinical Studies For Their First Anti-Viral Drug Targeted Against Bird Flu; Studies Are Being Conducted at the Beth Israel Deaconess Medical Center, a Teaching Hospital of Harvard Medical School 10/31/2005 8:00:09 AM WEST HAVEN, Conn., Oct 31, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC), today announced that it has commenced preclinical studies for its anti-viral drug FluCide-I(TM). The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, under the direction of Dr. Krishna Menon. Dr. Menon, the Company's Chief Regulatory Officer, explained that nanoviricides are complex materials. "We have started working on the basic safety of the polymer under a maximum tolerated dose protocol in mice. In the second part we will study the ligands that target FluCide-I(TM) to H5N1 and common influenza viruses. Thereafter, we will study the efficacy of FluCide-I(TM) itself against H5N1 and common influenza."
Dr. Anil Diwan, President, explained that, "if successful, the relevance of nanoviricides can be compared to the discovery of Penicillin, the very first bactericide. Prior to antibiotics, bacterial infections were treated with patient isolation, chicken soup and Vitamin C. Current anti-viral medicines can at best only partially inhibit the virus from multiplying in the human body. Although we cannot make claims of certainty yet, after we get good results from these studies we will be able to say that we have developed a true virus killer."
The Company is encouraged by the recent statements from high level international officials and health ministers of different countries concerning the urgency of developing effective vaccines and treatments and believes that a rapid regulatory approval of FluCide-I(TM), is possible should these studies be successful.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo*nanoviricides.com
NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug 11/7/2005 8:00:16 AM WEST HAVEN, Conn., Nov 07, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced that it has completed its initial safety studies on the major constituent of its anti-viral drug, FluCide-I(TM). The polymer which is unique and proprietary to NanoViricides, has been effectively tested for any toxic symptoms or for any ill effects in laboratory animals. The preliminary results were successful. More studies are being conducted for further detailed evaluations. The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School.
The Company will follow these studies with preliminary pre-clinical evaluations of certain ligands designed to specifically target the drug to H5N1 (avian flu) as well as common influenza viruses.
The Company's management has deemed this drug development project as its most urgent priority and believes that should FluCide-I(TM) prove successful in pre-clinicals, the timeline for regulatory approval in the later phases can be significantly shortened. The Company is encouraged by reports in Saturday's Wall St. Journal that the "FDA's acting head said that he is assembling a team of agency experts who will work to approve both antivirals and vaccines that would treat a pandemic flu virus."
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for anti-viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial with or without an encapsulated active pharmaceutical ingredient and a targeting ligand to a specific type of virus, like a guided missile.
SOURCE: NanoViricides, Inc. NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo*nanoviricides.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
